Clinical trial
A Study of Kidney and Cardiovascular Endpoints in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
NCT07900438 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Recruiting, started October 2026. Interventional study, Phase 4, 300 participants (estimated). Lead sponsor Novo Nordisk A/S; China. Primary measure: Time to first occurrence of a composite endpoint consisting of: Onset of persistent reduction of ≥ 50%...
How it compares
312 similar trials: same condition (Renal Insufficiency, Chronic) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of Kidney and Cardiovascular Endpoints in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- October 12, 2026
- Completion date
- January 24, 2030
- Enrollment
- 300 (estimated)
- Sites
- 26
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: cardiovascular risk, chronic kidney disease
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 26
- Countries
- China
- Lead sponsor
- Novo Nordisk A/S
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| Semaglutide | Experimental | Semaglutide |
Show registry wordingParticipants will receive subcutaneous injection of semaglutide once weekly. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Time to first occurrence of a composite endpoint consisting of: Onset of persistent reduction of ≥ 50% in eGFR compared with baseline, Onset of persistent eGFR < 15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy, Kidney death, CV death | From Baseline (Week 0) up to Week 169 |
Show registry wordingMeasured in month(s) | |
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Semaglutide
- US 11318191; expires February 17, 2041; assignee Novo Nordisk A S
- US 11478533; expires May 13, 2040; assignee Novo Nordisk A S
- US 11833248; expires February 1, 2039; assignee Novo Nordisk A S
- US 12396953; expires February 1, 2039; assignee Novo Nordisk A S
- US 12029779; expires October 10, 2038; assignee Novo Nordisk A S
- +36 more patents
Lead sponsor's other trials
Novo Nordisk A/S, most recent start first.
+1,402 more trials See the organization page
Similar trials
Same condition (Renal Insufficiency, Chronic) and phase, most recent start first.
+307 more trials See the condition page